The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study-Reference-Cited by-同舟云学术

The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study

Published:2016-10-05 Issue:1 Volume:36 Page:35-43
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

An Yuan,Liu Tian,He Dongyi,Wu Lijun,Li Juan,Liu Yi,Bi Liqi,Zhou Bin,Lin Changsong,He Lan,Liu Xiangyuan,Li Xiaofeng,Yang Niansheng,Zhang Zhuoli,Song Hui,Wei Wei,Liu Jing,Bi Yu,Li Zhanguo

Funder

Shanghai Roche Pharmaceutical Ltd.

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/s10067-016-3424-5.pdf

Reference38 articles.

1. Cross M, Smith E, Hoy D et al (2014) The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73:1316–1322. doi: 10.1136/annrheumdis-2013-204627

2. Woolf AD, Pfleger B (2003) Burden of major musculoskeletal conditions. Bull World Health Organ 81:646–656

3. Li R, Sun J, Ren LM et al (2012) Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. Rheumatology (Oxford) 51:721–729. doi: 10.1093/rheumatology/ker370

4. Zeng QY, Chen R, Darmawan J et al (2008) Rheumatic diseases in China. Arthritis Res Ther 10:R17. doi: 10.1186/ar2368

5. Zhang X, Mu R, Wang X et al (2015) The impact of rheumatoid arthritis on work capacity in Chinese patients: a cross-sectional study. Rheumatology (Oxford) 54:1478–1487. doi: 10.1093/rheumatology/kev014

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study;RMD Open;2024-06

2. Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study;Rheumatology and Therapy;2023-09-28

3. Adherence to biological therapies in patients with rheumatoid arthritis: a retrospective cohort study;Rheumatology International;2023-04-19

4. A fully human connective tissue growth factor blocking monoclonal antibody ameliorates experimental rheumatoid arthritis through inhibiting angiogenesis;BMC Biotechnology;2023-03-03

5. Elucidation of the anti-inflammatory mechanism of Er Miao San by integrative approach of network pharmacology and experimental verification;Pharmacological Research;2022-01